Parkinson’s Drug Targeting LRRK2 Fails Key Phase 2 Trial, Biogen and Denali Halt Development
Experimental Parkinson’s drug BIIB122 failed to slow disease in trials despite strong biological effects; development stopped.
/ 1654 items
#XY↓
Wall Street Turns Cautious on Summit Therapeutics: Bernstein Slaps Underperform Rating, Predicts Phase 3 Failures
Analysts warn Summit may fail key trials, lacks revenue, and faces pressure—raising doubts about its future and stock upside.
Hims & Hers Now Offers Affordable Generic Semaglutide in Canada
Hims & Hers offers cheaper generic semaglutide in Canada ($149/mo) with medical support for weight loss care.
Eli Lilly’s Retatrutide Delivers 28.3% Weight Loss in Phase 3 Trial, Analysts Stay Bullish
Eli Lilly’s retatrutide delivered 28.3% average weight loss at 80 weeks in Phase 3, with some patients reaching over 30% at 104 weeks. Analysts at Truist, Wolfe, and RBC stay bullish.
Medtronic to Acquire SPR Therapeutics for $650M to Expand Chronic Pain Treatment Options
Medtronic will buy SPR Therapeutics for a 60-day device that uses gentle nerve signals to reduce chronic pain without drugs.
BioMarin Plans FDA Submission After Positive VOXZOGO Hypochondroplasia Trial
BioMarin’s VOXZOGO improved growth in children with hypochondroplasia, showing strong trial results and good safety.